Esperion Therapeutics, Inc.

As of March 31, 2026, Esperion Therapeutics, Inc. carries a market capitalization of 606.70M, placing it among publicly traded companies globally. Its enterprise value stands at 690.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Esperion Therapeutics, Inc.'s next confirmed earnings release is scheduled for August 4, 2026.

As of March 31, 2026, Esperion Therapeutics, Inc. has 257.40M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1.44, and the price-to-book ratio stands at -2.28.

As of March 31, 2026, Esperion Therapeutics, Inc. trades at an EV/EBITDA multiple of 10.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.53 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 690.16M versus a market cap of 606.70M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Esperion Therapeutics, Inc. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -82.04, indicating conservative leverage, while an interest coverage ratio of 0.89 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -1.89, reflecting losses generated across the asset base. The company generates approximately 1.23M in revenue per employee across its workforce of 294.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.30 indicates how many times Esperion Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on July 10, 2026, Esperion Therapeutics, Inc.'s stock has gained approximately 165.84% over the past 52 weeks. The 50-day moving average sits at 2.73, while the 200-day moving average is 2.61.

Over the twelve months ended March 31, 2026, Esperion Therapeutics, Inc. generated 361.82M in revenue and converted that into -6.42M in net income, yielding earnings per share of -0.03. EBITDA reached 65.66M, while operating income came in at 65.56M.

As of March 31, 2026, Esperion Therapeutics, Inc. holds 135.09M in cash and equivalents against 218.55M in total debt, resulting in a net debt position of 81.24M. Total book value stands at -266.39M, with working capital of 137.64M providing operational flexibility.

Esperion Therapeutics, Inc. produced -15.73M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -163,503.90 in capital expenditures, free cash flow totaled -15.90M - equivalent to -0.07 per share.

Over the twelve months ended March 31, 2026, Esperion Therapeutics, Inc. posted a gross margin of 68.38, reflecting its pricing power and cost economics. The operating margin of 18.12 and net profit margin of -1.77 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Esperion Therapeutics, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.54, meaning Esperion Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Esperion Therapeutics, Inc. has an Altman Z-Score of -2.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.